Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 29 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 31 Jan 2018.
- 06 Oct 2017 Planned initiation date changed from 29 Sep 2017 to 31 Oct 2017.
- 17 May 2017 New trial record